Another study aimed to explore the synergistic effect of genetically engineered NDV LaSota L289A expressing anti-CTLA4 along with radiotherapy (10 Gy) as well as the systemic administration of anti-CTLA4 +NDV L289A+ radiotherapy (10 Gy) in a B16-F10 melanoma mouse model. Here, CTLA4 is linked to melanoma.